Biocytogen Pharmaceuticals (2315) Stock Overview

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH003, a humanized IgG2 agonistic monoclonal antibody targeting the CD40, a costimulatory protein found on antigen-presenting cells; and YH001, a humanized anti-CTLA-4, IgG1 monoclonal antibody. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human OX40 receptor; H004, a humanized IgG1 anti-4-1BB Agonists; YH005, an anti-Claudin 18.2 antibody; and YH008, an anti-PD-1/CD 40 bi-specific antibody for the treatment of solid tumors. In addition, its pre-clinical products include YH012 and YH013 for the treatment of solid tumor; YH015, a human IgG1 antagonistic monoclonal antibody to treat CD40; YH016 to treat oncology; and YH017 for the treatment of autoimmunity. Further, the company develops various products for the treatment of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company has a collaboration with CtM Biotech (Shanghai) Co., Ltd to co-develop a TCR-mimic Antibody-based Multi-Specific T Cell Engager targeting WT1/HLA-A02. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is based in Beijing, China.